# A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

> **NCT04179864** · PHASE1,PHASE2 · TERMINATED · sponsor: **Epizyme, Inc.** · enrollment: 102 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Tazemetostat
- **DRUG:** Abiraterone/prednisone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04179864
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-18
- **Primary completion:** 2024-11-04
- **Final completion:** 2024-11-04
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179864, "A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04179864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*